Pricing Log in Create free account
Saturday 17 October 2026 Export BLRX’s income statement to Excel — free account

BioLineRx Ltd.

BLRX Healthcare Biotechnology

BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024. In the quarter to June 2026, revenue fell 3.29%, EPS grew 23.0%, free cash flow fell 1,827.7% and total debt fell 40.2%, each against the same quarter a year earlier.

2.04 0.01 −0.49%
Market cap
$10.2M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
4/9
Altman Z
−13.80
Beneish M
−1.01
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 10.21
Revenue 1.39
Net Income (10.14)
Free Cash Flow (10.81)
Net Debt (6.38)
Current Ratio 1.20
Debt/Equity 0.40 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.45) (negative: loss-making)
P/S ratio 6.51
P/B ratio 0.55
Past 5Y EPS Growth —
This Y EPS Growth 94.33% (at or above 15%: strong)
Next Y EPS Growth 19.75% (at or above 15%: strong)
Next Y revenue growth 37.29% (at or above 10%: strong)
Next 5Y EPS Growth 57.36% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 6.27%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 43 20 21 13
Receivables 1 4 0 1
Inventory 2 3 2 2
Other — — — —
47 27 24 16
2023 2024 2025 Q'26
Payables 14 9 5 7
ST’ Debt 3 4 4 4
Other 25 2 2 2
43 15 12 14

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (6.88%) 1.17% (22.85%)

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 1
’24 7 5 5 12 29
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (3) — — —
’25 (3) 0 (2) (3) (8)
’24 (14) (11) (10) (9) (44)
’23 (8) (10) (10) 5 (23)
’22 (6) (6) (9) (6) (26)
’21 (6) (7) (5) (6) (24)
’20 (7) (6) (5) (5) (23)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (3) — — —
’25 (3) 0 (2) (3) (8)
’24 (14) (11) (10) (9) (44)
’23 (8) (10) (10) 5 (23)
’22 (6) (6) (9) (6) (27)
’21 (6) (7) (5) (6) (24)
’20 (7) (6) (5) (5) (23)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.36) (0.77) — — —
’25 1.39 (1.00) (0.22) (0.34) (0.29)
’24 (0.40) 0.24 (2.80) (1.56) (4.62)
’23 (6.00) (12.00) (12.00) (7.44) (37.60)
’22 (4.00) (6.40) (6.00) (3.60) (19.20)
’21 (10.80) (6.00) (4.84) (3.20) (24.00)
’20 (24.00) (18.00) (9.34) (24.40) (72.00)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 426.00 480.00 246.00 62.00 42.40 78.00 22.00 22.00 7.60 2.30

Analyst estimates 2026–2028

Powerpack
High 852.00 828.00 1,104.00 522.00 148.80 253.60 87.60 101.20 63.60 14.80
People
People Employees 43 51 48 42 38 38 49 79 28 24
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 1.03 0.05
Income, $m
Income, $m Revenue — — — — — — — 5 29 1
Gross margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.08 67.99 80.51
EBT (16) (24) (23) (25) (30) (27) (25) (61) (9) (2)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (1,262.79) (31.86) (171.69)
Net income (16) (24) (23) (25) (30) (27) (25) (61) (9) (2)
Depreciation 0 0 1 1 1 1 1 1 4 1
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.99 14.49 0.29
Earnings (167.92) (161.92) (125.94) (102.00) (72.00) (24.00) (19.20) (37.60) (4.62) (0.29)
Cash flow (155.05) (136.98) (133.66) (92.89) (55.07) (21.33) (20.34) (14.08) (21.97) (1.96)
Capex (0.59) (28.25) (56.44) (0.30) 0.00 (0.09) (0.24) (0.18) (0.03) (0.01)
Free cash flow (155.64) (165.23) (190.10) (93.19) (55.07) (21.42) (20.59) (14.27) (22.00) (1.97)
Book value 374.22 352.54 228.29 136.80 52.28 61.62 39.41 8.24 6.74 5.68
Shares, m 0 0 0 0 0 1 1 2 2 4
Valuation, ×
Valuation, × P/E — — — — — — — 0.00 0.00 0.00
P/S — — — — — — — 0.00 0.58 9.65
P/B — — — — — — — 7.43 1.25 0.49
EV/Sales — — — — — — — 0.00 0.37 (0.47)
EV/FCF — — — — — — — (2.84) (0.24) 0.07
Cash, $m
Cash, $m Operating cash flow (15) (21) (24) (23) (23) (24) (26) (23) (44) (8)
Capex 0 (4) (10) 0 — 0 0 0 0 0
Free cash flow (15) (25) (34) (23) (23) (24) (27) (23) (44) (8)
Balance, $m
Balance, $m Working capital 32 44 25 16 12 48 41 4 12 12
Total debt 0 0 9 8 6 4 10 10 13 9
Net debt (35) (49) (21) (19) (17) (53) (41) (33) (6) (12)
Shareholders’ equity 35 53 41 33 22 68 51 13 13 23
Returns, %
Returns, % ROA (35.11) (48.75) (39.18) (46.35) (59.53) (42.05) (31.63) (86.40) (17.93) (2.94)
ROIC 0.00 (432.43) (80.41) (122.16) (271.65) (100.28) (183.57) 0.00 (173.87) (56.36)
ROE (38.34) (55.40) (48.75) (68.13) (108.36) (60.04) (41.96) (189.23) (69.11) (6.38)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

BioLineRx Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PHIO Phio Pharmaceuticals Corp. $10.8M — (loss-making) — (loss-making) −8.70% (below 0%: shrinking) n/m −58.67% (below 0%: shrinking) 0.00% 0.00% Compare
TPST Tempest Therapeutics, Inc. $10.7M — (loss-making) — −71.57% (below 0%: shrinking) n/m +67.04% (above 0%: growing) 0.00% 0.00% Compare
KPRX Kiora Pharmaceuticals, Inc. $10.7M — (loss-making) — (loss-making) −93.64% (below 0%: shrinking) n/m +50.06% (above 0%: growing) 100.00% 0.00% Compare
GDTC CytoMed Therapeutics Limited $10.3M — (loss-making) — (loss-making) — n/m −27.39% (below 0%: shrinking) 0.00% — Compare
BLRX BioLineRx Ltd. $10.2M — (loss-making) — (loss-making) −3.29% (below 0%: shrinking) n/m −1,827.71% (below 0%: shrinking) 79.93% (1,215.31%)
LTRN Lantern Pharma Inc. $10.0M — (loss-making) — — n/m +25.31% (above 0%: growing) 0.00% 0.00% Compare
TOVX Theriva Biologics, Inc. $9.7M 0.1× — +33.08% (above 0%: growing) n/m +34.69% (above 0%: growing) 100.00% 0.00% Compare
BIVI BioVie Inc. $9.6M — (loss-making) — — n/m +26.50% (above 0%: growing) 0.00% 0.00% Compare
LSTA Lisata Therapeutics, Inc. $9.6M — (loss-making) — (loss-making) −98.30% (below 0%: shrinking) n/m +33.04% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $10.1M — — −71.57% — +29.77% 0.00% 0.00%

All 614 Biotechnology stocks →

BioLineRx Ltd. (BLRX) key facts

  • Concern: BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024.
  • BioLineRx Ltd. (BLRX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, BLRX traded at $2.04, a market capitalization of $10.2 million.
  • Return on equity was −6.38% and debt-to-equity 0.40.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −13.80 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

BioLineRx Ltd. (BLRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BLRX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com